Drugs / Presatovir
Trials 7
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-05-20 | Gilead Sciences | Results Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults gilead.com ↗
The study of GS-5806, an investigational oral RSV fusion inhibitor, achieved its primary and secondary endpoints of lower viral load (the amount of virus detected in the nasal wash), improvements in total mucus weight (the amount of mucus produced by the nose) and also symptom diary score compared to placebo. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-05-20 | Gilead Sciences | Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults gilead.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Presatovir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02254408 ↗ |
| Known as | GS-5806 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01797419 ↗ |
| Action | Inhibit | “We conducted a double-blind, placebo-controlled study of GS-5806, an oral RSV-entry inhibitor, in healthy adults who received a clinical challenge strain of RSV intranasally.” PMID 25140957 ↗ Aug 2014 |
| Modality | Small molecule | — CHEMBL3410450 ↗ |
| Route | Oral | “an oral RSV-entry inhibitor” PMID 25140957 ↗ Aug 2014 |